Prospective assessment of XPD Lys751Gln and XRCC1 Arg399Gln single nucleotide polymorphisms in lung cancer

Clinical Cancer Research

Volumn 13, Issue 10, 2007, Pages 2876-2881

  Giachino, Daniela F ^a   Ghio, Paolo ^b   Regazzoni, Silvia ^a   Mandrile, Giorgia ^a   Novello, Silvia ^b   Selvaggi, Giovanni ^b   Gregori, Dario ^a   DeMarchi, Mario ^a   Scagliotti, Giorgio V ^b  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; CARBOPLATIN; CISPLATIN; ETOPOSIDE; GEMCITABINE; GLUTAMINE; LYSINE; PROTEIN XRCC1; UNCLASSIFIED DRUG; XERODERMA PIGMENTOSUM GROUP D PROTEIN;

ADULT; AGED; AMINO ACID SUBSTITUTION; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; GENOTYPE; HETEROZYGOTE; HUMAN; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LUNG SURGERY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; AMINO ACID SUBSTITUTION; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SMALL CELL; DNA-BINDING PROTEINS; FEMALE; GLUTAMINE; HUMANS; LUNG NEOPLASMS; LYSINE; MALE; MIDDLE AGED; PLATINUM COMPOUNDS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVAL; TREATMENT OUTCOME; XERODERMA PIGMENTOSUM GROUP D PROTEIN;

EID: 34249812370     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-2543     Document Type: Article

References (34)

1. Relling MV, Dervieux T. Pharmacogenetics and cancer therapy. Nat Rev Cancer 2001;1:99-108.
2. Mohrenweiser HW, Wilson DM III, Jones IM. Challenges and complexities in estimating both the functional impact and the disease risk associated with the extensive genetic variation in human DNA repair genes. Mutat Res 2003;526:93-125.
3. Altaha R, Liang X, Yu JJ, Reed E. Excision repair cross complementing-group 1: gene expression and platinum resistance. Int J Mol Med 2004;14:959-70.
4. Lord RV, Brabender J, Gandara D, et al. Low ERCG expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 2002;8:2286-91.
5. Roseli R, Taron M, Alberala V, Massuti B, Felip E. Genetic testing for chemotherapy in non-small cell lung cancer. Lung Cancer 2003;41 Suppl 1:S97-102.
6. Benhamou S, Sarasin A. ERCC2/XPD gene polymorphisms and cancer risk. Mutagenesis 2002;17:463-9.
7. Hung RJ, Hall J, Brennan P, Boffetta P. Genetic polymorphisms in the base excision repair pathway and cancer risk: a HuGE review. Am J Epidemiol 2005;162:925-42.
8. Gurubhagavatula S, Liu G, Park S, et al. XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J Clin Oncol 2004;22:2594-601.
9. de las Penas R, Sanchez-Ronco M, Alberola V, et al. Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients. Ann Oncol 2006;17:668-75.
10. World Health Organization. The WHO handbook for reporting results of cancer treatment. Geneva, Switzerland, World Health Organization, 1979;68:pp. 8.
11. Hou SM, Falt S, Angelini S, et al. The XPD variant alleles are associated with increased aromatic DNA adduci level and lung cancer risk. Carcinogenesis 2002;23:599-603.
12. Hou SM, Ryk C, Kannio A, et al. Influence of common XPD and XRCC1 variant alleles on p53 mutations in lung tumors. Environ Mol Mutagen 2003;41:37-42.
13. Nelson HH, Kelsey KT, Mott LA, Karagas MR. The XRCC1 Arg399Gln polymorphism, sunburn, and non-melanoma skin cancer: evidence of gene-environment interaction. Cancer Res 2002;62:152-5.
14. Grambsh P, Therneau T. Proportional hazard tests and diagnostics based on weighted residuals. Biometrika 1994;81:515-26.
15. Hastie T, Tibshirani R. Non-parametric logistic and proportional odds regression. Appl Stat 1987;36:260-76.
16. Akaike H. Information theory as an extension of the maximum likelihood principle. In: CF, Petrov BN, editors. International Symposium on Information Theory. Budapest: Akademiai Kiado; 1973. p. 267-81.
17. Park DJ, Stoehlmacher J, Lenz HJ. Tailoring chemotherapy in advanced colorectal cancer. Curr Opin Pharmacol 2003;3:378-85.
18. Bosken CH, Wei Q, Amos CI, Spitz MR. An analysis of DNA repair as a determinant of survival in patients with non-small-cell lung cancer. J Natl Cancer Inst 2002;94:1091-9.
19. Lunn RM, Helzlsouer KJ, Parshad R, et al. XPD polymorphisms: effects on DNA repair proficiency. Carcinogenesis 2000;21:551-5.
20. Lindahl T, Wood RD. Quality control by DNA repair. Science 1999;286:1897-905.
21. Weaver DA, Crawford EL, Warner KA, et al. ABCC5, ERCC2, XPA and XRCCI transcript abundance levels correlate with cisplatin chemoresistance in non-small cell lung cancer cell lines. Mol Cancer 2005;4:18.
22. Spitz MR, Wu X, Wang Y, et al. Modulation of nucleotide excision repair capacity by XPD polymorphisms in lung cancer patients. Cancer Res 2001;61:1354-7.
23. Au WW, Salama SA, Sierra-Torres CH. Functional characterization of polymorphisms in DNA repair genes using cytogenetic challenge assays. Environ Health Perspect 2003;111:1843-50.
24. Hu Z, Ma H, Chen F, Wei Q, Shen H. XRCC1 polymorphisms and cancer risk: a meta-analysis of 38 case-control studies. Cancer Epidemiol Biomarkers Prev 2005;14:1810-8.
25. Divine KK, Gilliland FD, Crowell RE, et al. The XRCC1 399 glutamine allele is a risk factor for adenocarcinoma of the lung. Mutat Res 2001;461:273-8.
26. Casse C, Hu YC, Ahrendt SA. The XRCC1 codon 399 Gln allele is associated with adenine to guanine p53 mutations in non-small cell lung cancer. Mutat Res 2003;528:19-27.
27. Isla D, Sarries C, Rosell R, et al. Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. Ann Oncol 2004;15:1194-203.
28. Ryu JS, Hong YC, Han HS, et al. Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy. Lung Cancer 2004;44:311-6.
29. Wang ZH, Miao XP, Tan W, et al. Single nucleotide polymorphisms in XRCC1 and clinical response to platin-based chemotherapy in advanced non-small cell lung cancer. Ai Zheng 2004;23:865-8.
30. Yuan P, Miao XP, Zhang XM, et al. Polymorphisms in nucleotide excision repair genes XPC and XPD and clinical responses to platinum-based chemotherapy in advanced non-small cell lung cancer. Zhonghua Yi Xue Za Zhi 2005;85:972-5.
31. Quintela-Fandino M, Hitt R, Medina PP, et al. DNA-repair gene polymorphisms predict favorable clinical outcome among patients with advanced squamous cell carcinoma of the head and neck treated with cisplatin-based induction chemotherapy. J Clin Oncol 2006;24:4333-9.
32. Chung HK, Kim MK, Kim JW, et al. XRCC1 R399Q polymorphism is associated with response to platinum-based neoadjuvant chemotherapy in bulky cervical cancer. Gynecol Oncol 2006;103:1031-7.
33. De Ruyck K, Van Eijkeren M, Claes K, et al. Radiation-induced damage to normal tissues after radiotherapy in patients treated for gynecologic tumors: association with single nucleotide polymorphisms in XRCC1, XRCC3, and OGG1 genes and in vitro chromosomal radiosensitivity in lymphocytes. Int J Radiat Oncol Biol Phys 2005;62:1140-9.
34. Manuguerra M, Matullo G, Veglia F, et al. Multifactor dimensionality reduction applied to a large prospective investigation on gene-gene and gene-environment interactions. Carcinogenesis 2007;28:414-22.